Allianz Asset Management
DYN icon

Allianz Asset Management’s Dyne Therapeutics DYN Stock Holding History

Allianz Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Hold
15,000
– – ﹤0.01% 1913
2025
Q4 		$293K Buy
+15,000
New +$284K ﹤0.01% 1902
2025
Q1 		– Sell
-15,800
Closed -$372K – 2246
2024
Q4 		$372K Hold
15,800
– – ﹤0.01% 1948
2024
Q3 		$568K Hold
15,800
– – ﹤0.01% 1817
2024
Q2 		$558K Buy
15,800
+4,000
+34% +$116K ﹤0.01% 1797
2024
Q1 		$335K Buy
+11,800
New +$267K ﹤0.01% 1725

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Allianz Asset Management's DYN Position: Q1 2026 in Review

Allianz Asset Management held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 15,000 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Allianz Asset Management first reported a position in DYN in Q1 2024 and has held it in 6 quarters since. The position peaked at $568K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Allianz Asset Management held 15,000 shares of Dyne Therapeutics worth $272K as of Q1 2026.
  • Allianz Asset Management left its Dyne Therapeutics share count unchanged in Q1 2026.
  • Dyne Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1913 holding.
  • Allianz Asset Management first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Allianz Asset Management's Dyne Therapeutics position peaked at $568K in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.